Exemestane

Exemestane is a steroidal aromatase inhibitor used primarily in the treatment of estrogen-receptor-positive breast cancer in postmenopausal women. It works by irreversibly binding to the aromatase enzyme, which is responsible for converting androgens into estrogens. By inhibiting this conversion, exemestane significantly reduces estrogen levels in the body, thereby decreasing the growth stimulus for estrogen-dependent tumors.

Exemestane specifically interacts with the active site of the aromatase enzyme, leading to a permanent deactivation of the enzyme. This process is known as "suicide inhibition" because the inhibitor molecule (exemestane) is metabolized by the enzyme it inhibits, causing irreversible inactivation. This mechanism effectively lowers systemic estrogen concentrations, thus limiting the proliferation of hormone-sensitive cancer cells.

While the provided evidence does not directly elaborate on exemestane's mechanism, its established role in aromatase inhibition is critical for strategies aimed at reducing estrogen synthesis in certain cancers. Clinical studies, such as those involving exemestane compared with other treatments (NCT00002777), support its use in managing breast cancer.

Disclaimer: This content is for informational purposes only and not a substitute for professional medical advice. Always consult a healthcare provider regarding medical decisions.